Pharmacokinetics and Safety of Brexpiprazole Following Multiple‐Dose Administration to Japanese Patients With Schizophrenia

Brexpiprazole is currently approved in the United States for the treatment of schizophrenia and as adjunctive treatment of major depressive disorder. In Canada, it is approved for the treatment of schizophrenia. This study evaluated the pharmacokinetics (PK) and safety of brexpiprazole in Japanese p...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishigooka, Jun, Iwashita, Shuichi, Higashi, Koushi, Liew, Ei Leen, Tadori, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Pharmacokinetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763318/
https://www.ncbi.nlm.nih.gov/pubmed/28750151
http://dx.doi.org/10.1002/jcph.979

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763318/
https://www.ncbi.nlm.nih.gov/pubmed/28750151
http://dx.doi.org/10.1002/jcph.979

Ejemplares similares